HAEMONETICS CORP/MASS (HAE)
US4050241003 - Common Stock
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
In the world of growth stocks, NYSE:HAE shines as a value proposition.
Haemonetics (HAE) Shares Cross Above 200 DMA
Haemonetics 2nd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2025, which ended September 28, 2024,...
Haemonetics Larger Than S&P 500 Component Deckers Outdoor
Notable Tuesday Option Activity: APLS, HAE, LULU
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2025 financial results at 6:00 am...
Notable Thursday Option Activity: HAE, BA, PGY
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Haemonetics is Now Oversold (HAE)
Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient...
Relative Strength Alert For Haemonetics
Haemonetics Breaks Below 200-Day Moving Average - Notable for HAE
Haemonetics 1st Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are...
Sotera Health Appoints Christopher Simon to the Board of Directors
Haemonetics Announces CE Mark Certification for the SavvyWire® Pre-Shaped Pressure Guidewire
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better...
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am...
October 2025 Options Now Available For Haemonetics Corp. (HAE)
Haemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure Device
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient...
HAE Crosses Below Key Moving Average Level
Haemonetics Prices Upsized Private Placement of $600 Million Convertible Senior Notes
/PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2....
Haemonetics Announces Proposed Convertible Senior Notes Offering
/PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced its intention to offer, subject to market and other conditions,...
HAE Stock Earnings: Haemonetics Beats EPS, Beats Revenue for Q4 2024
HAE stock results show that Haemonetics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024.
Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations Website
/PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2024, which ended March 30, 2024,...